FTI Consulting Inc reports results for the quarter ended June 30 - Earnings Summary
FTI Consulting Inc reports results for the quarter ended June 30 - Earnings Summary
FTI Consulting Inc FCN.N reported quarterly adjusted earnings of $2.16 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $2.13. The mean expectation of three analysts for the quarter was for earnings of $2.26 per share. Wall Street expected results to range from $2.09 to $2.42 per share.
Revenue rose 5.3% to $993.46 million from a year ago; analysts expected $997.64 million.
FTI Consulting Inc's reported EPS for the quarter was $1.99.
The company reported quarterly net income of $57.81 million.
FTI Consulting Inc shares had risen by 14.4% this quarter and lost 0.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 7% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the business support services peer group is also "buy"
Wall Street's median 12-month price target for FTI Consulting Inc is $168.45, about 1.2% below its last closing price of $170.42
This summary was machine generated from LSEG data July 30 at 05:23 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 2.26 | 2.16 | Missed |
Mar. 31 2026 | 2.07 | 1.90 | Missed |
Dec. 31 2025 | 1.46 | 1.78 | Beat |
Sep. 30 2025 | 1.99 | 2.60 | Beat |
Recent news on FTI Consulting
See all newsBrief: Fti Consulting Appoints Christina Morris As A Senior Managing Director
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Redx Announces ROCKETEER Phase 2 Trial for RXC008
RCS - Redx Pharma Limited - Appointment of Chief Medical Officer
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition